DPP-Ⅳ抑制剂三维药效团模型构建
3D Pharmacophore Model Construction of DPP-Ⅳ Inhibitors
DOI: 10.12677/hjcet.2012.22010, PDF, HTML, 下载: 3,979  浏览: 14,420  国家科技经费支持
作者: 韩天佼, 李悦青*, 曹志, 赵伟杰：大连理工大学制药科学与技术学院；谷俊峰, 王希诚：大连理工大学工业装备结构分析国家重点实验室
关键词: Ⅱ型糖尿病；二肽基肽酶Ⅳ；药效团模型；数据库搜索
TypeⅡ Diabetes; Dipeptidyl-Peptidase IV; Pharmacophore Model; Database Searching
摘要: 以20个文献报道的二肽基肽酶Ⅳ(DPP-Ⅳ)抑制剂作为训练集，利用Discovery Studio构建了DPP-Ⅳ抑制剂的三维药效团模型。所得最优药效团模型Hypo1具有一个氢键受体，一个疏水基团，一个可离子化正电中心，一个芳香环和5个排除体积，Fischer交叉验证结果表明该模型具有较高的置信度。Hypo 1对测试集中20个DPP-Ⅳ抑制剂活性进行了预测，结果显示有较好的预测能力。利用该模型进行ZINC数据库搜索，得到预测活性小于10 nmol•L–1的化合物1369个。将这些化合物对接到DPP-Ⅳ的活性位点并根据PLP2评分函数筛选出21个评分较高的化合物，为设计和合成新型的DPP-Ⅳ抑制剂提供了理论参考。
Abstract: The 3D pharmacophore model of DPP-Ⅳ inhibitors was established using the Discovery Studio software with the training set of 20 DPP-Ⅳ inhibitors. The best pharmacophore hypothesis (Hypo 1) consists of one hydro- gen-bond acceptor, one hydrophobic point, one positive ionizable group, one aromatic ring as well as five excluded volumes. Fischer’s validation clearly shows that proposed Hypo 1 has highly predictive ability and can be efficiently used as a 3D query for virtual screening to retrieve potential inhibitors from ZINC databases. The hit compounds sub- sequently were docked into the DPP-Ⅳ active site and 21 compounds were obtained based on PLP2 scoring function. Therefore, this study could provide scientific basis for denovo design of DPP-Ⅳ inhibitors.
文章引用：韩天佼, 李悦青, 谷俊峰, 曹志, 赵伟杰, 王希诚. DPP-Ⅳ抑制剂三维药效团模型构建[J]. 化学工程与技术, 2012, 2(2): 53-60. http://dx.doi.org/10.12677/hjcet.2012.22010

参考文献

[1] H. Sakashita, F. Akahoshi, H. Kitajima, et al. [(S)-γ-(Arylamino) pro-lyl]thiazolidine compounds as a novel series of potent and stable DPP-Ⅳ inhibitors. Bioorganic and Medicinal Chemistry, 2006, 14(11): 3662-3671.
[2] 李祎亮, 王菊仙, 吴香玫等. 二肽基肽酶Ⅳ抑制剂的研究进展[J]. 中国新药杂志, 2008, 17(20): 1739-1744.
[3] T. Kondo, I. Sugimoto, T. Nekado, et al. Design and synthesis of long-acting inhibitors of dipeptidyl peptidase IV. Bioorganic and Me-dicinal Chemistry, 2007, 15(7): 2715-2735.
[4] C. F. Deacon, J. J. Holst. Dipeptidyl peptidase IV inhibitors: A promising new therapeutic approach for the management of type 2 diabetes. The International Journal of Biochemistry and Cell Biology, 2006, 38(5-6): 831-844.
[5] J. Y. Xu, L. Wei, R. Mathvink, et al. Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors. Bioorganic and Medicinal Chemistry Letters, 2005, 15(10): 2533- 2536.
[6] J. M. Cox, B. Harper, A. Mastracchio, et al. Discovery of 3- aminopiperidines as potent, selective, and orally bioavailable dipep-tidyl peptidase Ⅳ inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17(16): 4579-4583.
[7] J. Feng, Z. Y. Zhang, M. B. Wallace, et al. Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase Ⅳ. Journal of Me-dicinal Chemistry, 2007, 50(10): 2297-2300.
[8] D. Kim, J. E. Kowalchick, S. D. Edmondson, et al. Tria- zolopiperazine-amides as dipeptidyl peptidase Ⅳ inhibitors: Close analogs of JANUVIATM (sitagliptin phosphate). Bioor- ganic and Medicinal Chemistry Letters, 2007, 17(12): 3373- 3377.
[9] T. Yoshida, H. Sakashita, F. Akahoshi, et al. [(S)-γ-(4-Aryl-1- piperazinyl)-L-prolyl]thiazolidines as a novel series of highly potent and long-lasting DPP-IV inhibitors. Bioorganic and Me- dicinal Chemistry Letters, 2007, 17(9): 2618-2621.
[10] I. L. Lu, K. C. Tsai, Y. K. Chiang, et al. A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors. European Journal of Medicinal Chemistry, 2008, 43(8): 1603- 1611.
[11] E. B. Villhauer, J. A. Brinkman, G. B. Naderi, et al. 1-[[(3- Hy- droxy-1-adamantyl)amino] acetyl]-2-cyano-(S)-pyrrolidine: A po- tent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. Journal of Medici- nal Chemistry, 2003, 46(13): 2774-2789.
[12] S. D. Edmondson, A. Mastracchio, J. L. Duffy, et al. Discovery of potent and selective orally bioavailable β-substituted phenyla- lanine derived dipeptidyl peptidase Ⅳ inhibitors. Bioorganic and Medicinal Chemistry Letters, 2005, 15(12): 3048-3052.
[13] D. Kim, L. P. Wang, M. Beconi, et al. (2R)-4-Oxo-4-[3-(trifluoro- methyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2, 4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipep- tidyl peptidase Ⅳ inhibitor for the treatment of type 2 diabetes. Journal of Medicinal Chemistry, 2005, 48(1): 141-151.
[14] S. D. Edmondson, A. Mastracchio, M. Beconi, et al. Potent and selective proline derived dipeptidyl peptidase Ⅳ inhibitors. Bio- organic and Medicinal Chem-istry Letters, 2004, 14(20): 5151- 5155.
[15] S. W. Wright, M. J. Am-mirati, K. M. Andrews, et al. Cis-2,5- dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: Syn- thesis and in vitro, in vivo, and X-ray crystallographic charac- terization. Journal of Medicinal Chemistry, 2006, 49(11): 3068- 3076.
[16] S. M. Sheehan, H. J. Mest, B. M. Watson, et al. Discovery of non-covalent dipeptidyl peptidase Ⅳ inhibitors which induce a conformational change in the active site. Bioorganic and Me- dicinal Chemistry Letters, 2007, 17(6): 1765-1768.
[17] M. Eckhardt, E. Langkopf, M. Mark, et al. 8-(3-(R)-amino- piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. Journal of Medicinal Chem- istry, 2007, 50(26): 6450-6453.
[18] 鲍红娟, 张燕玲, 乔延江. HMG-CoA 还原酶抑制剂三维药效团的构建[J]. 物理化学学报, 2008, 24(2): 301-306.
[19] F. G. Osman. Pharmacophore perception, development, and use in drug design. International University Line, 2000: 259-260.
[20] S. Sakkiah, S. Thangapandian, S. John, et al. 3D QSAR phar- macophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. European Journal of Medical Chemistry, 2010, 45(6): 2132-2140.
[21] J. E. Kowalchick, B. Leiting, K. D. Pryor, et al. Design, synthe- sis, and biological evalua-tion of triazolopiperazine-based β- amino amides as potent, orally active dipeptidyl peptidase Ⅳ (DPP-4) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17(21): 5934-5939.
[22] D. Ferra-ris, Y. S. Ko, D. Calvin, et al. Ketopyrrolidines and ketoazetidines as potent dipeptidyl peptidase Ⅳ (DPP Ⅳ) in- hibitors. Bioorganic and Medicinal Chemistry Letters, 2004, 14 (22): 5579-5583.
[23] Y. Hu, L. F. Ma, M. Wu, et al. Synthesis and structure-activity relationship of N-alkyl Gly-boro-Pro inhibitors of DPP4, FAP, and DPP7. Bioorganic and Medicinal Chemistry Letters, 2005, 15(19): 4239-4242.
[24] http://www.changbioscience.com/stat/corr.html
[25] J. J. Irwin, B. K. Shoichet. ZINC—A free database of comer- cially available compounds for virtual screening. Journal of Chemical Infor-mation and Modeling, 2004, 45(1): 177-182.